Cargando…
The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia
PURPOSE OF REVIEW: We aimed to summarize recent guidelines, position papers, and high-quality clinical research relating the use of nutraceuticals in the management of individuals at high risk of atherosclerotic cardiovascular disease. RECENT FINDINGS: It is essential that individuals at high risk o...
Autores principales: | Penson, Peter E., Banach, Maciej |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501132/ https://www.ncbi.nlm.nih.gov/pubmed/32945980 http://dx.doi.org/10.1007/s11883-020-00887-z |
Ejemplares similares
-
Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?
por: Cicero, Arrigo F. G., et al.
Publicado: (2021) -
Managing of Dyslipidaemia Characterized by Accumulation of Triglyceride-Rich Lipoproteins
por: Visser, Jolien, et al.
Publicado: (2022) -
RNA Silencing in the Management of Dyslipidemias
por: Henney, Neil C., et al.
Publicado: (2021) -
Oral Lipid-Lowering Treatments Beyond Statins: Too Old and Outdated or Still Useful?
por: Parhofer, Klaus G.
Publicado: (2021) -
Selective Peroxisome Proliferator–Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?
por: Fruchart, Jean-Charles, et al.
Publicado: (2020)